Nicolas Sireau

Sirgartan believes that mental illness should no longer be underestimated and stigmatised. Sirgartan Therapeutics is a clinical-stage drug development company established with the vision to transform the treatment paradigm for OCD (obsessive compulsive disorder) and deliver life-changing medicines for patients with this condition, many of whom are poorly treated with current therapies. The company is working with the University of Cambridge, UK on a first-in-class treatment based on modulation of glutamate. Investment obtained through initial seed-funding has enabled advanced pre-clinical studies to be carried out by the University of Cambridge. These studies have shown very encouraging results, much to the satisfaction of Professor Trevor Robbins, Chief Scientific Advisor to Sirgartan, and to the submission of a patent application for the identified therapy and its method of action. The organisation is now seeking further funding to enable progression into clinical studies. Please contact us should you or your organisation have an interest in joining us on the journey.